| Vol. 10.01 – 14 January, 2021 |
| |
|
|
| Researchers identified a novel short isoform of angiotensin-converting enzyme 2 (ACE2) expressed in the airway epithelium, the main site of SARS-CoV-2 infection. Short ACE2 was substantially upregulated in response to interferon stimulation and rhinovirus infection, but not SARS-CoV-2 infection. [Nature Genetics] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Using both a SARS-CoV-2 virus pseudotype and authentic SARS-CoV-2, scientists found that overexpression of AXL in HEK293T cells promoted SARS-CoV-2 entry as efficiently as overexpression of ACE2, while knocking out AXL significantly reduced SARS-CoV-2 infection in H1299 pulmonary cells and in human primary lung epithelial cells. [Cell Research] |
|
|
|
| The authors found that SARS-CoV-2 replication induced a delayed interferon response in lung epithelial cells. By screening 16 putative sensors involved in sensing of RNA virus infection, they found that MDA5 and LGP2 primarily regulated IFN induction in response to SARS-CoV-2 infection. [Cell Reports] |
|
|
|
| Investigators established an immortalized human lung pericyte cell line. Developed using SV40 large T antigen lentivirus, immortalized pericytes exhibited stable SV40T expression, sustained proliferation, and had significantly higher telomerase activity compared to normal human lung pericytes. [Laboratory Investigation] |
|
|
|
| Human airway epithelial cells were used to test the efficacy of cyclic AMP modulation by ABCC4 and PDE-4 inhibition through a series of concentration–response studies. [Scientific Reports] |
| |
|
|
| Researchers identified circNDUFB2 to be downregulated in NSCLC tissues, and to negatively correlate with NSCLC malignant features. [Nature Communications] |
|
|
|
| Investigators confirmed that CB1 receptor (CB1R) was expressed in NSCLC cells in this study. Arachidonoylcyclopropylamide (ACPA) as a synthetic, CB1R-specific ligand decreased proliferation rate in NSCLC cells by WST-1 analysis and real-time proliferation assay. [Cell Death & Disease] |
|
|
|
| Researchers inferred that CXCR4 confers resistance to ionizing radiation (IR) in NSCLC cells. Further, on the basis of colony forming ability, they found that drug-resistant A549/GR cells with improved CXCR4 expression exhibited more resistance to IR than A549 cells evidenced along with a reduction in the formation of γ-H2AX foci after IR. [Cell Death & Disease] |
|
|
|
| Scientists observed that nuclear factor-erythroid 2-related factor 2 (Nrf2) suppression following treatment with brusatol in NSCLC cells with either exogenously introduced kelch-like ECH-associated protein 1 or siNrf2 resulted in the inhibition of cell migration and invasion, with shrinking cell morphology due to decreased focal adhesions via inhibition of the RhoA–ROCK1 pathway. [Scientific Reports] |
|
|
|
|
| The authors discuss how the view of the airway epithelial landscape has evolved with the advent of transcriptomic approaches to cellular phenotyping, with a focus on epithelial interactions with the local neuronal and immune systems. [Nature Reviews Immunology] |
|
|
|
|
| The Pulmonary Fibrosis Foundation announced enrollment of the first patient in PRECISIONS clinical trial. This is the first clinical trial to apply the principles of precision medicine to the treatment of patients with idiopathic pulmonary fibrosis. [Pulmonary Fibrosis Foundation] |
|
|
|
| Innovent Biologics, Inc. announced that the National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application for TYVYT® in combination with BYVASDA® as first-line therapy for patients with HCC. [Innovent Biologics, Inc.] |
|
|
|
|
| February 3 – 23, 2021 Virtual |
|
|
|
|
|
| STEMCELL Technologies, Inc. – Burnaby, British Columbia, Canada |
|
|
|
| University of California, San Francisco – San Francisco, California, United States |
|
|
|
| Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| The University of Tennessee Health Science Center – Memphis, Tennessee, United States |
|
|
|
| The University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
|